From biomarker discovery to precision medicine
Recent breakthroughs in immuno-oncology and liquid biopsy research translate into a paradigm shift with regards to understand cancer evolution and how to manipulate the body’s own immune response to mount an attack against tumour cells.
Thank you for visiting our booth at EACR25. If you did not have a chance to visit our booth learn more from what our scientists presented at exhibitor spotlight and scientific session.
Scientific session—Evidence for antigen-driven TCR𝜷 chain convergence in the tumor infiltrating T cell repertoire of 148 research subjects with melanoma
Geoffrey M. Lowman (on behalf of T. Looney)
Senior Staff Scientist,
Thermo Fisher Scientific
Immuno-oncology NGS assays news
Ion Torrent Oncomine TCR Beta-SR Assay specifically interrogates the CDR3 region of the TCR beta chain. Compatible with both FFPE DNA and RNA, this short-read sequencing assay enables characterisation of the immune status, and detection of T cell minimal residual disease (MRD) in the peripheral blood.
Oncomine Tumor Mutation Load Assay is a robust, targeted next-generation sequencing (NGS) assay providing clinical researchers with an accurate quantification of somatic mutation counts to assess tumour mutation load from limited formalin- fixed, paraffin-embedded (FFPE) samples.
Liquid biopsy custom solutions
Learn more about our latest technology innovation Ion AmpliSeq HD Panels for targeted next generation sequencing. This innovative technology gives you the power to design your own panels and find variants with a low limit of detection—down to 0.1% for cell-free DNA samples.
Find out more about our key technologies and products below.
Explore our resources for your cancer research